BioPharmX Corporation Granted Pre-IND Meeting With U.S. FDA To Review Its Topical Acne Solution

MENLO PARK, Calif., Jan. 12, 2015 /PRNewswire/ -- BioPharmX Corporation (OTCQB: BPMX), a biotechnology company focused on the development of novel drug delivery products to address unmet needs in large, well-defined and underserved markets, today announced that it has been granted a pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration to discuss the company's topical antibiotic acne compound currently under development.  The meeting, currently scheduled for March 2015, is expected to focus on the company's proposed strategy for advancing its acne program and plans for conducting safety and toxicology studies, along with human clinical trials. 

"We're very pleased with the FDA's decision to grant a meeting with BioPharmX and with our continued progress toward advancing the development of our topical antibiotic acne compound," said Jim Pekarsky, chief executive officer and co-founder of BioPharmX. 

About BioPharmX Corporation
BioPharmX Corporation (OTCQB: BPMX) is a Silicon Valley-based biotechnology company, which seeks to provide innovative products through unique, proprietary platform technologies for prescription, over-the-counter ("OTC"), and supplement applications in the fast-growing health and wellness markets, including women's health, dermatology, and otolaryngology (ears, nose & throat).  To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements
Statements in this news release relating to the business of BioPharmX, which are not historical facts, are "forward-looking statements."  These forward-looking statements may be identified by words such as "expect," "anticipate," "believe," or similar expressions that are intended to identify such forward-looking statements.  All forward-looking statements are expressly qualified in their entirety by this cautionary statement and the risks and other factors detailed in the company's filings with the Securities and Exchange Commission (SEC). These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risk that BioPharmX is unable to obtain FDA approval for its topical antibiotic acne compound or other products and that the meeting with the FDA does not occur as scheduled. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements.  The forward-looking statements included in this news release are made only as of the date hereof and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.  

BioPharmX is a pending trademark of BioPharmX Inc. 

SOURCE BioPharmX Corporation

Related Links

http://www.biopharmx.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED